Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
47
TELO.V Quote, Financials, Valuation and Earnings
Last price:
$0.06
Seasonality move
:
-10.31%
Day range:
$0.06 - $0.06
52-week range:
$0.05 - $0.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.75x
Volume:
31K
Avg. volume:
188K
1-year change:
-54.17%
Market cap:
$5.5M
Revenue:
--
EPS (TTM):
-$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TELO.V
Telo Genomics Corp.
|
-- | -- | -- | -- | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
XLY.TO
Auxly Cannabis Group, Inc.
|
$35.9M | -- | 18.12% | -- | $0.2500 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TELO.V
Telo Genomics Corp.
|
$0.06 | -- | $5.5M | -- | $0.00 | 0% | -- |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
|
XLY.TO
Auxly Cannabis Group, Inc.
|
$0.1500 | $0.2500 | $202.3M | 4.92x | $0.00 | 0% | 1.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TELO.V
Telo Genomics Corp.
|
-- | 0.076 | -- | 0.77x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
|
XLY.TO
Auxly Cannabis Group, Inc.
|
27.67% | -1.082 | 33.75% | 1.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TELO.V
Telo Genomics Corp.
|
-$2.8K | -$540.7K | -398.51% | -398.51% | -- | -$302.8K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
|
XLY.TO
Auxly Cannabis Group, Inc.
|
$8.8M | -$4.1M | 22.71% | 34.07% | -10.27% | $8.3M |
Telo Genomics Corp. vs. Competitors
-
Which has Higher Returns TELO.V or COOL.CX?
Core One Labs, Inc. has a net margin of -- compared to Telo Genomics Corp.'s net margin of --. Telo Genomics Corp.'s return on equity of -398.51% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TELO.VTelo Genomics Corp.-- -$0.01 -$26.7K COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About TELO.V or COOL.CX?
Telo Genomics Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Telo Genomics Corp. has higher upside potential than Core One Labs, Inc., analysts believe Telo Genomics Corp. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TELO.VTelo Genomics Corp.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is TELO.V or COOL.CX More Risky?
Telo Genomics Corp. has a beta of -0.397, which suggesting that the stock is 139.747% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock TELO.V or COOL.CX?
Telo Genomics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telo Genomics Corp. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TELO.V or COOL.CX?
Telo Genomics Corp. quarterly revenues are --, which are larger than Core One Labs, Inc. quarterly revenues of --. Telo Genomics Corp.'s net income of -$541.7K is higher than Core One Labs, Inc.'s net income of --. Notably, Telo Genomics Corp.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telo Genomics Corp. is -- versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TELO.VTelo Genomics Corp.-- -- -- -$541.7K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns TELO.V or CURE.X.CX?
Biocure Technology has a net margin of -- compared to Telo Genomics Corp.'s net margin of --. Telo Genomics Corp.'s return on equity of -398.51% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TELO.VTelo Genomics Corp.-- -$0.01 -$26.7K CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About TELO.V or CURE.X.CX?
Telo Genomics Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Telo Genomics Corp. has higher upside potential than Biocure Technology, analysts believe Telo Genomics Corp. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings TELO.VTelo Genomics Corp.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is TELO.V or CURE.X.CX More Risky?
Telo Genomics Corp. has a beta of -0.397, which suggesting that the stock is 139.747% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TELO.V or CURE.X.CX?
Telo Genomics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telo Genomics Corp. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TELO.V or CURE.X.CX?
Telo Genomics Corp. quarterly revenues are --, which are larger than Biocure Technology quarterly revenues of --. Telo Genomics Corp.'s net income of -$541.7K is higher than Biocure Technology's net income of --. Notably, Telo Genomics Corp.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telo Genomics Corp. is -- versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TELO.VTelo Genomics Corp.-- -- -- -$541.7K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns TELO.V or HEAL.CX?
has a net margin of -- compared to Telo Genomics Corp.'s net margin of --. Telo Genomics Corp.'s return on equity of -398.51% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TELO.VTelo Genomics Corp.-- -$0.01 -$26.7K HEAL.CX-- -- -- -
What do Analysts Say About TELO.V or HEAL.CX?
Telo Genomics Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Telo Genomics Corp. has higher upside potential than , analysts believe Telo Genomics Corp. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings TELO.VTelo Genomics Corp.0 0 0 HEAL.CX0 0 0 -
Is TELO.V or HEAL.CX More Risky?
Telo Genomics Corp. has a beta of -0.397, which suggesting that the stock is 139.747% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TELO.V or HEAL.CX?
Telo Genomics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telo Genomics Corp. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TELO.V or HEAL.CX?
Telo Genomics Corp. quarterly revenues are --, which are larger than quarterly revenues of --. Telo Genomics Corp.'s net income of -$541.7K is higher than 's net income of --. Notably, Telo Genomics Corp.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telo Genomics Corp. is -- versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TELO.VTelo Genomics Corp.-- -- -- -$541.7K HEAL.CX-- -- -- --
-
Which has Higher Returns TELO.V or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -- compared to Telo Genomics Corp.'s net margin of --. Telo Genomics Corp.'s return on equity of -398.51% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TELO.VTelo Genomics Corp.-- -$0.01 -$26.7K NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About TELO.V or NSHS.CX?
Telo Genomics Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Telo Genomics Corp. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Telo Genomics Corp. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TELO.VTelo Genomics Corp.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is TELO.V or NSHS.CX More Risky?
Telo Genomics Corp. has a beta of -0.397, which suggesting that the stock is 139.747% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock TELO.V or NSHS.CX?
Telo Genomics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telo Genomics Corp. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TELO.V or NSHS.CX?
Telo Genomics Corp. quarterly revenues are --, which are smaller than NanoSphere Health Sciences, Inc. quarterly revenues of --. Telo Genomics Corp.'s net income of -$541.7K is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Telo Genomics Corp.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telo Genomics Corp. is -- versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TELO.VTelo Genomics Corp.-- -- -- -$541.7K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
-
Which has Higher Returns TELO.V or XLY.TO?
Auxly Cannabis Group, Inc. has a net margin of -- compared to Telo Genomics Corp.'s net margin of 51.36%. Telo Genomics Corp.'s return on equity of -398.51% beat Auxly Cannabis Group, Inc.'s return on equity of 34.07%.
Company Gross Margin Earnings Per Share Invested Capital TELO.VTelo Genomics Corp.-- -$0.01 -$26.7K XLY.TOAuxly Cannabis Group, Inc.22.15% $0.01 $238.5M -
What do Analysts Say About TELO.V or XLY.TO?
Telo Genomics Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Auxly Cannabis Group, Inc. has an analysts' consensus of $0.2500 which suggests that it could grow by 66.67%. Given that Auxly Cannabis Group, Inc. has higher upside potential than Telo Genomics Corp., analysts believe Auxly Cannabis Group, Inc. is more attractive than Telo Genomics Corp..
Company Buy Ratings Hold Ratings Sell Ratings TELO.VTelo Genomics Corp.0 0 0 XLY.TOAuxly Cannabis Group, Inc.1 0 0 -
Is TELO.V or XLY.TO More Risky?
Telo Genomics Corp. has a beta of -0.397, which suggesting that the stock is 139.747% less volatile than S&P 500. In comparison Auxly Cannabis Group, Inc. has a beta of 1.254, suggesting its more volatile than the S&P 500 by 25.413%.
-
Which is a Better Dividend Stock TELO.V or XLY.TO?
Telo Genomics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Auxly Cannabis Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telo Genomics Corp. pays -- of its earnings as a dividend. Auxly Cannabis Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TELO.V or XLY.TO?
Telo Genomics Corp. quarterly revenues are --, which are smaller than Auxly Cannabis Group, Inc. quarterly revenues of $39.9M. Telo Genomics Corp.'s net income of -$541.7K is lower than Auxly Cannabis Group, Inc.'s net income of $20.5M. Notably, Telo Genomics Corp.'s price-to-earnings ratio is -- while Auxly Cannabis Group, Inc.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telo Genomics Corp. is -- versus 1.50x for Auxly Cannabis Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TELO.VTelo Genomics Corp.-- -- -- -$541.7K XLY.TOAuxly Cannabis Group, Inc.1.50x 4.92x $39.9M $20.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 23
UniFirst Corp. [UNF] is up 0.77% over the past day.
